PMN net incomeQ2 2026-$11.73M
PMN net income was -$11.73M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$10.12M a year earlier. For the full fiscal 2025 it was -$39.72M, compared with $2.78M in fiscal 2024.
ProMIS Neurosciences Inc. (PMN) financials
For the twelve months ended Jun 30, 2026, ProMIS Neurosciences Inc. reported -$42.23M of net income.
- Net income, TTM
- -$42.23M
- Cash
- $53.43M
- Market cap
- $36.3M
FY2021FY2025
FY2021FY2022
PMN revenue and earnings growth
PMN EPSQ2 2026-$1.28
PMN diluted EPS was -$1.28 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$22.61.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Research and development | $33.38M | $10.64M | $7.88M | $16.09M | $4.63M |
| Selling, general and admin | $6.79M | $6.19M | $6.38M | $7.29M | $3.66M |
| Operating income | -$40.17M | -$16.83M | -$14.26M | -$23.38M | -$8.29M |
| Income tax | - | $0 | $0 | $0 | - |
| Net income | -$39.72M | $2.78M | -$13.21M | -$18.06M | -$9.79M |
| EPS, basic | -$22.61 | $2.68 | -$26.75 | -$60.25 | -$42.25 |
| EPS, diluted | -$22.61 | $2.63 | -$26.75 | -$60.25 | -$42.25 |
| Diluted shares | 1.8M | 1.1M | 491,708.28 | 300,104.36 | 231,424.68 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $6.12M | $13.29M | $12.60M | $5.88M | $16.94M |
| Short-term investments | $33.8K | $33.1K | $32.4K | $31.0K | $33.2K |
| Current assets | $9.18M | $18.91M | $13.62M | $6.90M | $17.71M |
| Total assets | $9.18M | $18.91M | $13.62M | $6.92M | $17.75M |
| Current liabilities | $10.41M | $2.22M | $9.35M | $6.41M | $929.1K |
| Total debt | - | - | $0 | - | $3.91M |
| Total liabilities | $10.44M | $2.42M | $9.87M | $8.27M | $12.09M |
| Shareholders' equity | -$1.26M | $16.49M | $3.75M | -$1.35M | $5.66M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$28.12M | -$27.18M | -$10.84M | -$17.03M | -$9.31M |
| Capital expenditures | - | - | - | $2.0K | $6.0K |
| Free cash flow | - | - | - | -$17.04M | -$9.31M |
| Investing cash flow | -$702 | -$693 | -$1.3K | -$2.0K | $94.6K |
| Financing cash flow | $20.94M | $27.88M | $17.75M | $6.49M | $25.52M |
| Stock-based compensation | $857.6K | $825.8K | $271.5K | $487.6K | $515.6K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $9.52M | $6.97M | $9.37M | $9.80M | $8.75M | $5.46M | $4.32M | $2.56M | $1.63M | $2.12M | $2.23M | $1.14M |
| Selling, general and admin | $2.74M | $1.67M | $1.40M | $1.95M | $1.43M | $2.00M | $1.68M | $1.87M | $1.09M | $1.55M | $1.65M | $1.38M |
| Operating income | -$12.27M | -$8.64M | -$10.77M | -$11.75M | -$10.18M | -$7.46M | -$6.00M | -$4.43M | -$2.71M | -$3.68M | -$3.87M | -$2.52M |
| Interest expense | - | - | - | - | - | - | - | $1 | -$1 | $76.8K | - | $75.4K |
| Net income | -$11.73M | -$8.24M | -$10.67M | -$11.58M | -$10.12M | -$7.35M | -$238.2K | $9.28M | -$2.62M | -$3.64M | -$3.58M | -$2.36M |
| EPS, basic | -$1.28 | -$1.26 | - | -$6.00 | -$7.26 | -$5.27 | - | $7.75 | -$3.25 | -$4.75 | - | -$4.75 |
| EPS, diluted | -$1.28 | -$1.26 | - | -$6.00 | -$7.26 | -$5.27 | - | $7.75 | -$3.25 | -$4.75 | - | -$4.75 |
| Diluted shares | 9.1M | 6.5M | - | 2.0M | 1.4M | 1.4M | - | 1.2M | 790,829.56 | 781,359.04 | - | 494,833.2 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $53.43M | $63.81M | $6.12M | $15.40M | $4.51M | $8.36M | $13.29M | $21.54M | $992.5K | $2.50M | $12.60M | $16.87M |
| Short-term investments | $33.8K | $33.8K | $33.8K | $33.1K | $33.1K | $33.1K | $33.1K | $32.4K | $32.4K | $32.4K | $32.4K | $31.8K |
| Current assets | $56.69M | $65.61M | $9.18M | $21.46M | $9.51M | $13.65M | $18.91M | $24.51M | $1.41M | $3.55M | $13.62M | $17.86M |
| Total assets | $56.69M | $67.41M | $9.18M | $21.46M | $9.51M | $13.65M | $18.91M | $24.51M | $1.41M | $3.55M | $13.62M | $17.88M |
| Current liabilities | $7.22M | $6.61M | $10.41M | $12.21M | $9.82M | $4.06M | $2.22M | $2.64M | $3.17M | $2.65M | $9.35M | $9.85M |
| Total debt | - | - | - | - | - | - | - | - | - | - | $0 | - |
| Total liabilities | $7.29M | $6.69M | $10.44M | $12.27M | $9.89M | $4.17M | $2.42M | $17.24M | $3.69M | $3.47M | $9.87M | $11.12M |
| Shareholders' equity | $49.40M | $60.72M | -$1.26M | $9.19M | -$382.6K | $9.47M | $16.49M | $7.27M | -$2.28M | $77.1K | $3.75M | $6.75M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.39M | -$12.38M | -$9.28M | -$10.06M | -$3.85M | -$4.93M | -$8.72M | -$6.67M | -$1.50M | -$10.29M | -$3.76M | -$2.38M |
| Financing cash flow | $0 | $70.08M | -$1 | - | - | - | $470.0K | $27.22M | $0 | $190.3K | -$510.6K | - |
| Stock-based compensation | $408.9K | $189.4K | $203.2K | $197.1K | $212.0K | $245.3K | $623.2K | $121.0K | $18.0K | $63.6K | $4.8K | $0 |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 7.85 | 9.92 | 0.88 | 1.76 | 0.97 | 3.36 | 8.52 | 9.30 | 0.44 | 1.34 | 1.46 | 1.81 |
| Debt to equity | - | - | - | - | - | - | - | - | - | - | 0.00 | - |
Source: XBRL data ProMIS Neurosciences Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Mar 25, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
PMN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PMN | - | - | -$42.23M | - | $36.3M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
PMN FAQ
4 questionsIs PMN profitable?
No. ProMIS Neurosciences Inc. reported a net loss of $42.23M for the twelve months ended Jun 30, 2026.How much cash and debt does PMN have?
ProMIS Neurosciences Inc. reported $53.43M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did PMN last report financial results?
The latest statements here come from ProMIS Neurosciences Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this PMN financial data come from?
Quantisnow builds these statements from the structured XBRL data ProMIS Neurosciences Inc. files with the SEC. It is provided for information only and is not investment advice.